Sarah Souza, NP
Nurse Practitioner · North Dartmouth, MANPI 1225558968
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,119 of the $16,082 with a category attached, or 62.9%. 28 manufacturers reported payments, led by SK Life Science, Inc. at 37.1% of the total. Reporting peaked in 2024 at $7,401 and has fallen 68.5% since, to $2,329 in 2025. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 411 payments — averaging $39.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$6K
- AbbVie$3K
- Livanova USA, Inc.$2K
- Lilly USA, LLC$893
- Lundbeck LLC$690
- Biohaven Pharmaceutical Holding Company Ltd.$434
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$4,62529%
- Travel & lodging$1,2388%
- Food & beverage$10,11963%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 55 | $5,969 |
| AbbVie | 105 | $2,588 |
| Livanova USA, Inc. | 11 | $2,078 |
| Lilly USA, LLC | 44 | $893 |
| Lundbeck LLC | 26 | $690 |
| Biohaven Pharmaceutical Holding Company Ltd. | 34 | $434 |
| Novartis | 16 | $418 |
| Teva Pharmaceuticals USA, Inc. | 13 | $358 |
| Biohaven Pharmaceuticals, Inc. | 9 | $354 |
| Pfizer | 29 | $348 |
| Johnson & Johnson | 11 | $308 |
| Biogen | 9 | $270 |
| EMD Serono, Inc. | 6 | $200 |
| Genentech USA, Inc. | 9 | $199 |
| Eisai Inc. | 6 | $163 |
| Bristol Myers Squibb | 5 | $146 |
| Amgen | 4 | $113 |
| CSL Behring | 3 | $89 |
| Sunovion Pharmaceuticals Inc. | 1 | $82 |
| TG Therapeutics, Inc. | 2 | $76 |
| Acorda Therapeutics, Inc | 4 | $74 |
| UCB, Inc. | 2 | $67 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| Neurelis, Inc. | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$4,977
- VNS Therapy$1,920
- UBRELVY$571
- NURTEC ODT$355
- VYEPTI$234
- KISUNLA$229
- QULIPTA$223
- Ponvory$125
How this compares
$16,082 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 15 | $565,966 |
| Nurtec OdtRimegepant Sulfate | 123 | $225,274 |
| BotoxOnabotulinumtoxina | 110 | $137,926 |
| Kesimpta PenOfatumumab | 12 | $134,346 |
| CopaxoneGlatiramer Acetate | 21 | $119,701 |
| Emgality PenGalcanezumab-Gnlm | 124 | $100,991 |
| UbrelvyUbrogepant | 66 | $89,932 |
| NuplazidPimavanserin Tartrate | 14 | $72,763 |
| AptiomEslicarbazepine Acetate | 22 | $47,890 |
| XcopriCenobamate | 40 | $44,695 |
| QuliptaAtogepant | 33 | $36,608 |
| FingolimodFingolimod Hcl | 23 | $29,636 |
| Emgality SyringeGalcanezumab-Gnlm | 30 | $22,020 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $19,285 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $10,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta | $2,588 | $264,466209 claims |
| PfizerNurtec Odt | $348 | $225,274123 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $358 | $119,70121 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $82 | $47,89022 claims |
| SK Life Science, Inc.Xcopri | $5,969 | $44,69540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in North Dartmouth
- Lauri WelchNorth Chelmsford$110K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
- Lauren BurkeBoston$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.